Less could be better: The case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia

Pediatric Transplantation

Volumn 17, Issue 4, 2013, Pages 326-327

  Hussein, Ayad A ^a   Frangoul, Haydar ^b  

^a KING HUSSEIN CANCER CENTER   (Jordan)

^b MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; CHILDHOOD DISEASE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; EDITORIAL; FAILURE FREE SURVIVAL; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM SURVIVAL; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); WHOLE BODY RADIATION;

ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84878017070     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12088     Document Type: Editorial

References (15)

1. Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet 1972: 1: 284-289.
2. Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R,. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood 1998: 92: 2742-2749.
3. Kojima S, Horibe K, Inaba J, et al. Long-term outcome of acquired aplastic anaemia in children: Comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000: 111: 321-328.
4. Unal S, Cetin M, Tavil B, Caliskan N, Yetgin S, Uckan D,. Favorable outcome with allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia patients. Pediatr Transplant 2007: 11: 788-791.
5. Korthof ET, Bekassy AN, Hussein AA,. Management of acquired aplastic anemia in children. Bone Marrow Transplant 2013: 48: 191-195.
6. Kamio T, Ito E, Ohara A, et al. Relapse of aplastic anemia in children after immunosuppressive therapy: A report from the Japan Childhood Aplastic Anemia Study Group. Haematologica 2011: 96: 814-819.
7. Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008: 111: 1054-1059.
8. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: A report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007: 92: 11-18.
9. Passweg JR, Marsh JC,. Aplastic anemia: First-line treatment by immunosuppression and sibling marrow transplantation. Hematology Am Soc Hematol Educ Program 2010: 2010: 36-42.
10. Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: Conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 2011: 17: 291-299.
11. Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: A retrospective study from the EBMT-SAA Working Party. Haematologica 2010: 95: 976-982.
12. Eapen M, Ramsay NK, Mertens AC, Robison LL, Defor T, Davies SM,. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol 2000: 111: 754-760.
13. Sanders JE, Woolfrey AE, Carpenter PA, et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 2011: 118: 1421-1428.
14. Chung N-GL, Wook J, Jang P-S, Jeong D-C, Cho B, Kim H-K,. Reduced dose cyclophosphamide, fludarabine and anti-thymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia. Pediatr Transplant 2013: 387-393
15. Tolar J, Deeg HJ, Arai S, et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: Early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant 2012: 18: 1007-1011.